-
公开(公告)号：US20050171009A1
公开(公告)日：2005-08-04
申请号：US11089777
申请日：2005-03-25
IPC分类号： A61K9/08 , A61K9/00 , A61K38/28 , A61K45/08 , A61K47/02 , A61K47/04 , A61K47/08 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/34 , A61K47/36 , A61K47/42 , A61P3/10 , A61K31/225 , A61K31/7024
CPC分类号： A61K31/7032 , A61K9/0019 , A61K38/28 , A61K47/26 , A61K2300/00
摘要： The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物，胰岛素衍生物及其组合的多肽的药物制剂; 表面活性剂或两种或更多种表面活性剂的组合; 任选的防腐剂或两种或多种防腐剂的组合; 和任选的等渗剂，缓冲剂或其它赋形剂或其组合，所述药物制剂具有在酸性范围内的pH。
-
公开(公告)号：US07713930B2
公开(公告)日：2010-05-11
申请号：US12328208
申请日：2008-12-04
IPC分类号： A61K38/28
CPC分类号： A61K31/7032 , A61K9/0019 , A61K38/28 , A61K47/26 , A61K2300/00
摘要： The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物，胰岛素衍生物及其组合的多肽的药物制剂; 表面活性剂或两种或更多种表面活性剂的组合; 任选的防腐剂或两种或多种防腐剂的组合; 和任选的等渗剂，缓冲剂或其它赋形剂或其组合，所述药物制剂具有在酸性范围内的pH。
-
公开(公告)号：US07476652B2
公开(公告)日：2009-01-13
申请号：US11089777
申请日：2005-03-25
IPC分类号： A61K38/28
CPC分类号： A61K31/7032 , A61K9/0019 , A61K38/28 , A61K47/26 , A61K2300/00
摘要： The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物，胰岛素衍生物及其组合的多肽的药物制剂; 表面活性剂或两种或更多种表面活性剂的组合; 任选的防腐剂或两种或多种防腐剂的组合; 和任选的等渗剂，缓冲剂或其它赋形剂或其组合，所述药物制剂具有在酸性范围内的pH。
-
公开(公告)号：US20100216692A1
公开(公告)日：2010-08-26
申请号：US12773356
申请日：2010-05-04
IPC分类号： A61K38/28
CPC分类号： A61K31/7032 , A61K9/0019 , A61K38/28 , A61K47/26 , A61K2300/00
摘要： The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物，胰岛素衍生物及其组合的多肽的药物制剂; 表面活性剂或两种或更多种表面活性剂的组合; 任选的防腐剂或两种或多种防腐剂的组合; 和任选的等渗剂，缓冲剂或其它赋形剂或其组合，所述药物制剂具有在酸性范围内的pH。
-
公开(公告)号：US09707176B2
公开(公告)日：2017-07-18
申请号：US13509507
申请日：2010-11-11
CPC分类号： A61K9/08 , A61K9/0019 , A61K38/2278 , A61K38/26 , A61K47/10 , A61K47/183 , A61P3/10
摘要： A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.
-
6.发明申请公开(公告)号：US20120283179A1
公开(公告)日：2012-11-08
申请号：US13509507
申请日：2010-11-11
CPC分类号： A61K9/08 , A61K9/0019 , A61K38/2278 , A61K38/26 , A61K47/10 , A61K47/183 , A61P3/10
摘要： A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.
摘要翻译： 一种液体组合物，其包含GLP-1激动剂或/和其药理学上可耐受的盐和任选的至少一种药学上可接受的赋形剂，其中所述组合物包含甲硫氨酸，作为二甲双胍和/或长效胰岛素/ 适当的胰岛素衍生物。
-
公开(公告)号：US20090082255A1
公开(公告)日：2009-03-26
申请号：US12328208
申请日：2008-12-04
CPC分类号： A61K31/7032 , A61K9/0019 , A61K38/28 , A61K47/26 , A61K2300/00
摘要： The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
摘要翻译： 本发明涉及包含选自胰岛素，胰岛素代谢物，胰岛素类似物，胰岛素衍生物及其组合的多肽的药物制剂; 表面活性剂或两种或更多种表面活性剂的组合; 任选的防腐剂或两种或多种防腐剂的组合; 和任选的等渗剂，缓冲剂或其它赋形剂或其组合，所述药物制剂具有在酸性范围内的pH。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
